Comparisons
Tirzepatide vs. semaglutide: what the SURMOUNT-5 head-to-head trial actually showed
SURMOUNT-5 was the first head-to-head RCT comparing tirzepatide and semaglutide. Tirzepatide produced 20.2% vs 13.7% average weight loss at 72 weeks. Here's what those numbers mean — and don't mean.
3 min read · Updated 2026-05-25
Peptide GPS publishes educational information, not medical advice. We don't sell, prescribe, or recommend specific medications, dosages, or providers. Always discuss any therapy with a licensed clinician.
Key takeaways
- In SURMOUNT-5, participants on tirzepatide lost an average of 20.2% of body weight at 72 weeks, compared to 13.7% for semaglutide (estimated treatment difference: -6.6 percentage points)
- The trial enrolled adults with obesity without type 2 diabetes — the results don't directly apply to people with T2D
- A 2026 meta-analysis (PubMed PMID 41723034) across multiple studies confirmed tirzepatide produces significantly greater weight reduction (mean difference -4.61%)
- Both drugs are FDA-approved for weight management; tolerability, dosing schedule, and cost all affect which may be appropriate for a specific person
- A greater average in a trial and the right choice for you are two different things
What SURMOUNT-5 was designed to test
SURMOUNT-5 (NCT05822830) was a 72-week, randomized, open-label Phase 3b trial. It enrolled 751 adults with or overweight with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) and without , across the U.S. and Puerto Rico.
Participants were randomized 1:1 to maximum tolerated doses of either (up to 15 mg once weekly) or (up to 2.4 mg once weekly). Most reached the maximum dose: 89.3% received at least one dose of tirzepatide 15 mg, and 92.8% received at least one dose of semaglutide 2.4 mg.
The primary objective was to demonstrate tirzepatide's superiority in percentage body weight change at 72 weeks.
The key findings: 20.2% vs 13.7% at 72 weeks
At 72 weeks, tirzepatide produced an average 20.2% reduction in body weight versus 13.7% with semaglutide. The estimated treatment difference was -6.6 percentage points, which was statistically significant.
Participants on tirzepatide were also more likely to achieve larger percentage losses: more likely than those on semaglutide to reach at least 10%, 15%, or 20% body weight reduction.
A 2026 meta-analysis (PubMed PMID 41723034) that pooled results across multiple comparison studies confirmed the direction and magnitude: tirzepatide produced a mean difference of -4.61% greater weight reduction across studies. The SURMOUNT-5 result is consistent with the broader evidence base.
How these drugs differ mechanistically
Semaglutide is a . It mimics glucagon-like peptide-1, a hormone that reduces appetite and slows .
Tirzepatide is a : it activates both GLP-1 and (glucose-dependent insulinotropic polypeptide) receptors. GIP receptors are found in brain regions involved in appetite regulation. The combined activation is thought to explain why tirzepatide produces greater average weight loss. This is a different mechanism, not simply a stronger version of the same one.
What the trial doesn't tell us
SURMOUNT-5 enrolled a specific population: adults without type 2 diabetes, with at least one of four specific comorbidities, in the U.S. and Puerto Rico. The results don't necessarily extend to people with T2D, those without comorbidities, or broader demographic groups.
The trial was open-label — participants knew which drug they were taking — which can introduce bias in subjective outcomes. Side-effect profiles weren't compared as a primary endpoint, and individual tolerance varies significantly. Nausea, vomiting, constipation, and diarrhea are the most common GI effects for both drugs.
Cost and insurance coverage differ by plan, year, and formulary status. Access to the maximum dose may vary in your specific situation.
What remains uncertain
Long-term cardiovascular outcomes comparing tirzepatide and semaglutide head-to-head are not yet available. Both drugs have separate cardiovascular outcome trials: SURPASS-CVOT (tirzepatide) and SELECT (semaglutide 2.4 mg). Those trials studied different populations and are not direct comparisons.
How individual patients respond varies. Trial averages reflect the middle of a distribution — some patients respond more strongly to semaglutide; some respond less strongly to tirzepatide than the average.
Questions to ask your clinician
- Based on my health profile and the SURMOUNT-5 data, is one drug more appropriate for me?
- What do you expect in terms of tolerability differences between tirzepatide and semaglutide for my situation?
- How does my insurance coverage affect this decision right now?
- How do we know if the medication is working, and what's the plan if I'm not responding as expected?
What to track
- Your weight loss percentage at 12 and 24 weeks — early response can predict longer-term outcomes
- Side effect patterns in the first weeks of each dose increase
- Cardiometabolic markers your prescriber is monitoring
Making sense of the numbers for your situation
SURMOUNT-5 showed tirzepatide produced greater average weight loss than semaglutide in this specific trial population. That is meaningful clinical evidence. It doesn't make tirzepatide the right choice for every person — tolerability, dosing, coverage, and your medical history all matter.
Talk to your prescriber about which drug fits your situation. Trial averages are a starting point for the conversation, not the end of it.
Get the weekly brief
One plain-English email per week on GLP-1s, peptides, and the regulation around them.